Oncotelic Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2017
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2017
Net Income	249.28	-4.52	-7.9	5.09	-9.39	Upgrade
Depreciation & Amortization	-	-	-	0.01	0.06	Upgrade
Other Amortization	0.2	0.12	0.3	1.98	1.45	Upgrade
Asset Writedown & Restructuring Costs	-	3.2	6.08	-12.84	-	Upgrade
Loss (Gain) From Sale of Investments	-365.35	-	-0.01	-	-	Upgrade
Stock-Based Compensation	2.38	-	-	0.9	1.18	Upgrade
Provision & Write-off of Bad Debts	-	-	0	-	-	Upgrade
Other Operating Activities	112	0.11	0.3	2.6	1.95	Upgrade
Change in Accounts Payable	0.11	0.3	-0.05	0.8	0.22	Upgrade
Change in Other Net Operating Assets	0	0.05	-0.04	-0	0.08	Upgrade
Operating Cash Flow	-1.38	-0.74	-1.32	-1.45	-4.43	Upgrade
Short-Term Debt Issued	0.91	0.66	1.41	0.97	3.07	Upgrade
Long-Term Debt Issued	0.48	-	-	-	-	Upgrade
Total Debt Issued	1.39	0.66	1.41	0.97	3.07	Upgrade
Short-Term Debt Repaid	-	-	-0.04	-	-0.5	Upgrade
Total Debt Repaid	-	-	-0.04	-	-0.5	Upgrade
Net Debt Issued (Repaid)	1.39	0.66	1.38	0.97	2.56	Upgrade
Issuance of Common Stock	-	-	-	0.16	1.97	Upgrade
Other Financing Activities	-	-	-0.13	-	-	Upgrade
Financing Cash Flow	1.39	0.66	1.25	1.13	4.53	Upgrade
Net Cash Flow	0	-0.08	-0.07	-0.33	0.09	Upgrade
Cash Interest Paid	0.37	0.37	0.39	0.4	0.3	Upgrade
Cash Income Tax Paid	0	0	0	-	-	Upgrade
Levered Free Cash Flow	-1.12	-0.31	-0.58	-3.27	-4.24	Upgrade
Unlevered Free Cash Flow	-0.77	0.1	-0.23	-3.39	-4.44	Upgrade
Change in Working Capital	0.11	0.35	-0.09	0.8	0.31	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.